We are the leader in discovering and commercializing clinically relevant blood-based proteomic tests for lung cancer.
While genomic data uncovers the potential genetic drivers of cancer (tumor), proteomic data profiles the patient’s (host) immune response to their cancer. Both are critical elements for interpreting the real-time complexity of the cancer disease state (cancer ecosystem).
Image adapted from Chen and Mellman 2016 for educational purposes.
We are experts at profiling the patient's immune response to their cancer with blood-based proteomic solutions in addition to traditional genomic insights. Our mass spectrometry and machine learning expertise allows us to identify clinically relevant proteomic differences in patient populations to help guide treatment strategy.
We use Matrix Assisted Laser Desorption/Ionization Time of Flight (MALDI-ToF) mass spectrometry to broadly interrogate the circulating proteome without the need to identify specific proteins in advance.
We use LC-MS for both targeted and discovery proteomics. This includes quantification of predefined highly-multiplexed sets of proteins with MRM-MS and unbiased discovery proteomics with SWATH / DIA-MS.
